CMG-DIGITAL
25.4.2022 01:02:06 CEST | Business Wire | Press release
Global digital design and smart production agency CMG Digital is today relaunching as part of an ongoing evolution of its company brand.
The agency, based in Croatia, with a presence in the UK and the US, now has a new vision and is dedicating itself to putting humanity back into digital.
The acceleration of digital adoption during the pandemic brought many positives to the digital space, including investment, faster development, new services and virtual worlds. At the same time, it has also tackled issues around security, privacy, sustainability and inefficiencies.
More significantly, the acceleration of digital has seen a move towards automation and away from humanisation in digital.
The relaunched CMG Digital is the answer: an agency dedicated to supporting clients to ensure they can maximise success in digital within this context.
The new vision will also be accompanied by a new look. With the agency debuting a new logo, theme and tone of voice. The updated visual identity will represent the evolved brand values.
Putting humanity at the core of its company was an easy decision for the agency, which boasts two thirds of women holding the top management positions as well as women making up more than 55% of the overall employees. CMG Digital also boasts a mental health program called MindGiving to support the team: this includes yoga classes, managing stress workshops, meeting limits, no meeting Friday as well as additional health insurance.
Explaining the new vision, Ana Tolić, President of CMG said:
“We are both delighted and excited to enter this new era of CMG Digital history and focus on our mission of putting humanity back into digital.
“Over the course of the pandemic the lightning-fast adoption of digital meant the space quickly became inhuman and cold.
“We are an agency that recognises that we can’t replace the people's side of things with a platform, and that relationships are critical to success. We believe in focusing on B2H – Business to Human.”
The relaunch will also keep digital sustainability at the heart of the agency.
CMG Digital is known for setting the industry tone when it comes to sustainability. Historically, the agency standardised recycling long before it became compulsory. Now, it is leading the way once more and focussing on standardising its approach to digital sustainability.
As global-to-local experts, CMG Digital puts a strong focus on maximising content life through reuse, recycling and repurposing to reduce the digital waste of its clients.
This focus is allowing CMG Digital to spread its message, educate and upskilling clients and brands in digital sustainability as well as digital inclusivity.
CMG Digital hopes that its position as a leader in its field will enable it to set the tone and encourage other agencies to follow its example. The agency is a powerhouse in its industry, credited with delivering over 50,000 projects, working with more than 200 global brands and delivering to over 100 markets worldwide. Since 2001 it has been the digital custodian of some of the world’s most valuable brands across the globe, and today leading digital deployment for multinational corporations such as P&G, GSK, Novartis, ConvaTec, Cloetta, Edgewell and Rimac.
CMG Digital believes its relaunch will help it better achieve its overall goal of empowering brands to scale their global message to the local level with consistency and pace.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005009/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
